Loading
Life sciences · Journal article
Frontiers in Oncology · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Transformed small cell lung cancer (T-SCLC) is most commonly observed in EGFR-mutant lung adenocarcinoma and represents an important mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). Its reported clinical incidence is approximately 3%-10%. Patients with T-SCLC often experience rapid disease progression and poor overall prognosis, and no established standard treatment regimen is currently available. We report a case of advanced EGFR-mutant lung adenocarcinoma with RB1, TP53, and BRCA2 co-mutations that underwent small-cell transformation during treatment. Small-cell transformation was detected through close surveillance and confirmed by repeat biopsy. The patient subsequently received individualized multimodal therapy, including chemotherapy, targeted therapy, and local radiotherapy, and remained alive 43 months after the initial diagnosis.